Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Volcano888 who wrote (5133)	11/29/1999 6:30:00 PM
From: BDR	Read Replies (1) \| Respond to of 10293

Zicam/GUMM- understand that I have no position in GUMM. Buying Zicam was done in the interest of "due diligence". I am skeptical about GUMM given the games they have played with the publication of their data and with the homeopathic labeling of something that does not seem to meet the criteria for a homeopathic medicine for no other reason than to avoid the scrutiny of the FDA. Other than that, I am neutral.(g) TGX- continuing to grow, selling a lot of product and data still supports the technique. There was a recent study that indicated palladium had fewer complications/side effects than iodine which may be true but the results are so operator dependent that it may be hard to know. Seed implant treatments are increasing in number and rapidly. At the same time the number of radicals is decreasing along with the death rate from prostate cancer and the number of newly diagnosed cases, if recent data is to be believed. I am not long TGX anymore. My concern has to do with the fact that, despite obstacles to entry, there are several new players in the game and I believe at least one of them is offering palladium seeds. Unless TGX can somehow extract a premium for their brand seeds may be on their way to becoming a commodity.